Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant (NCT05027906)

🧪 Interventions in This Study

• AT-1501 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (9 Sites)

• University of Cincinnati — Cincinnati, Ohio
• Royal Prince Alfred Hospital — Camperdown, New South Wales
• Royal Adelaide Hospital — Adelaide, South Australia
• Fundação Oswaldo Ramos - Hospital do Rim — São Paulo,
• Providence Health Care - St. Paul's Hospital — Vancouver, British Columbia
• Vancouver General Hospital — Vancouver, British Columbia
• McGill University Health Care Centre — Montreal, Quebec
• Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital — Liverpool,
• Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital — Oxford,

📞 Contact the Study Coordinator

Phone: (949) 238-8090

Email: clinicaltrials@eledon.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Prevention of Rejection in Kidney Transplant clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.